Introduction {#S0001}
============

Cervical cancer is one of the most common gynecological malignancies worldwide. Approximately 30% of cervical cancers are known to relapse eventually after initial treatment \[[@CIT0001]\]. Most women who recur are not curable. However, early identification of recurrence can alter disease management or treatment-planning options, particularly for those with a central pelvic recurrence and no evidence of metastasis. A large number of noninvasive imaging methods can be used to identify patients with recurrent cervical cancer. These methods are used in conjunction with physical examination and measurement of squamous cell carcinoma antigen (SCC) levels. Elevated SCC values are established indicators of the active disease and can be used for early detection \[[@CIT0002]\]; however, they do not identify the site of recurrence \[[@CIT0002]\]. Various modalities such as computed tomography (CT) and positron emission tomography (PET) play important roles in the staging of these tumors.

Computed tomography is helpful in determining the radiation portal, site for biopsy, and effect of treatment. Consequently, this modality has been used as a very effective tool in the diagnosis of recurrent uterine cervical cancer. However, with CT, recurrence from postoperative and postradiation fibrosis may be difficult to differentiate, and normal-sized metastatic lymph nodes are hard to detect \[[@CIT0003], [@CIT0004]\]. Positron emission tomography is an emerging imaging technique that is used to diagnose cancer recurrence and distant metastasis in the preclinical stage before the disease becomes evident in conventional diagnostic imaging modalities. However, PET does not provide anatomic information, and precise localization of any suspicious lesion may be difficult. Early diagnosis of cancer recurrence by PET is also impaired by the presence of increased uptake in physiologic, nonpathologic, or inflammatory states \[[@CIT0005], [@CIT0006]\].

Squamous cell carcinoma measurements suffer from relatively low sensitivity and specificity for detecting recurrent cervical cancer (76.3% and 70.6%, respectively). The reported sensitivities of imaging methods range from 78% to 93% for CT, 80% to 100% for PET, 83% to 100% for PET/CT imaging, and 86% to 99% for PET using the tracer fluorine 18 (18F)-fluorodeoxyglucose (FDG). No consensus on the most sensitive imaging method for the detection of recurrence in patients treated for cervical cancer is found.

A meta-analysis enables the comparison of various imaging methods through a systematic review of the literature. The process involves combining previously published work and making a summary estimate of the sensitivity and specificity of each imaging modality \[[@CIT0007]\]. The purpose of our present study is to perform a comprehensive systematic review to determine the overall diagnostic performance of PET alone, PET/CT, and CT for the detection of recurrent cervical cancer on a per-patient and a per-lesion basis. To our knowledge, this type of study has not been previously reported.

Material and methods {#S0002}
====================

Literature search {#S20003}
-----------------

A comprehensive computer literature search of study abstracts involving human subjects was performed to identify articles on the diagnostic performance of PET (interpreted with or without the use of CT) and CT to detect recurrent ovarian cancer. MEDLINE and EMBASE databases were reviewed from January 1980 to June 2013 using the following key words: ("PET" or "positron emission tomography" or "FDG" or "fluorodeoxyglucose" or "CT" or "computed tomography") and ("cervical carcinoma" or "cervical cancer" or "carcinoma of cervix") and ("sensitivity" or "specificity" or "false negative" or "false positive" or "diagnosis" or "detection" or "accuracy"). Other databases, including CancerLit and the Cochrane Library, were also searched for relevant articles. Reference lists of included studies and review articles were manually searched.

Selection of studies {#S20004}
--------------------

Two investigators independently checked the retrieved articles. Disagreements were resolved by consensus. The inclusion criteria were (a) articles were published in English; (b) PET alone, PET/CT, and CT (alone or in combination, but not in sequence) were used to identify and characterize recurrent cervical carcinoma; (c) histopathological analysis and/or close clinical follow-up for at least 6 months were used as reference; (d) for per-patient statistics, sufficient data were presented to calculate the true-positive (TP), false-negative (FN), false-positive (FP), and true-negative (TN) values; (e) 10 or more patients were included; and (f) when data or subsets of data were presented in more than one article, the article with the most detail or the most recent article was chosen. Authors of abstracts and studies that did not report sufficient data were contacted to request additional information.

Data extraction {#S20005}
---------------

The same observers independently extracted relevant data on study characteristics and examination results using a standardized form. To resolve disagreements between reviewers, a third reviewer assessed all discrepant items, and the majority opinion was used for analysis.

To ensure accuracy in the analyses, we extracted the following items: description of study population (age); study design (prospective, retrospective, or unknown); patient enrollment (consecutive or not); and interpretation of test results (blinded or not). The following features were also included: for PET alone or PET/CT, the amount of tracer and type of analysis (qualitative, quantitative, or both); and for CT, the section thickness and use or non-use of a contrast agent. The numbers of TP, FN, FP, and TN results in the detection of recurrent cervical cancer were extracted on a per-patient or per-lesion basis.

Statistical analysis {#S20006}
--------------------

The statistical software "Meta-Disc" version 1.40 was used to analyze separately the 18F-FDG PET, 18F-FDG PET/CT, and CT data. We calculated the pooled sensitivity, specificity, and diagnostic odds ratio (DOR) for each modality. We also calculated the summary receiver operating characteristic curves (SROC) and the \*Q index (which is the optimum statistical method for reflecting the diagnostic value). The \*Q index is defined by the point at which sensitivity and specificity are equal, which is closest to the ideal top-left corner of the SROC space \[[@CIT0008], [@CIT0009]\]. The *Z*-test was then performed to determine whether the sensitivity, specificity, DOR, and \*Q index of one modality are significantly different from those of the others. The χ^2^-test was used to assess the heterogeneity among the studies included in the meta-analysis. A fixed-effect model (FEM) was used when homogeneity existed among different studies, whereas a random-effect model (REM) was used when heterogeneity was found.

Results {#S0007}
=======

Study identification and eligibility {#S20008}
------------------------------------

A total of 118 articles in English were initially retrieved from the MEDLINE and EMBASE databases. Twenty-six articles were considered as candidates after a review of titles and abstracts. Two articles were excluded for using CT-magnetic resonance imaging (MRI). Finally, the remaining 23 were included in the study \[[@CIT0003], [@CIT0010]--[@CIT0031]\].

Study description {#S20009}
-----------------

The characteristics of participants in the 23 eligible studies are outlined in [Table I](#T0001){ref-type="table"}. The mean age of the participants ranged from 41 years to 58 years. Of the 23 studies, 1 \[[@CIT0019]\] enrolled patients prospectively, whereas 15 \[[@CIT0003], [@CIT0011], [@CIT0013]--[@CIT0018], [@CIT0024]--[@CIT0026], [@CIT0028]--[@CIT0031]\] were retrospective database reviews. The status of the remaining 7 studies was not defined \[[@CIT0010], [@CIT0012], [@CIT0020]--[@CIT0023], [@CIT0031]\]. Seven studies \[[@CIT0013], [@CIT0022], [@CIT0024]--[@CIT0026], [@CIT0028], [@CIT0031]\] enrolled patients in a consecutive manner, including three studies \[[@CIT0021], [@CIT0024], [@CIT0027]\] in which the operator was blinded to prior test results. The TP, FN, FP, and TN results, as well as some features of each modality, are shown in [Tables II](#T0002){ref-type="table"}--[IV](#T0004){ref-type="table"}.

###### 

Main characteristics of the included studies

  Author          Year of publication   Age, mean (range)   Patients selection   Blind   Evaluable patients or lesion   Recurrent number *n* (%)   Noninvasive modalities   Study design
  --------------- --------------------- ------------------- -------------------- ------- ------------------------------ -------------------------- ------------------------ -----------------
  Walsh           1981                  ND (23--68)         Consecutive          ND      33                             29 (88)                    CT                       Retrospectively
  Heron           1988                  45 (28--80)         ND                   ND      64                             26 (41)                    CT                       ND
  William         1989                  ND                  ND                   ND      20                             11 (55)                    CT                       Retrospectively
  Park            2000                  53 (ND)             ND                   ND      36                             19 (53)                    PET, CT                  ND
  Sun             2001                  ND                  ND                   ND      20                             18 (90)                    PET                      Retrospectively
  Belhocine       2002                  52 (38--66)         ND                   ND      60                             28 (47)                    PET                      Retrospectively
  Nakamoto        2002                  52 (26--82)         ND                   ND      20                             5 (25)                     PET                      Retrospectively
  Ryu             2003                  51 (31--78)         ND                   ND      249                            31 (12)                    PET                      Retrospectively
  Havrilesky      2003                  42 (28--69)         ND                   ND      29                             22 (76)                    PET                      Retrospectively
  Lai             2004                  51 (25--87)         Consecutive          ND      400                            67 (17)                    PET                      Retrospectively
  Yen             2004                  51 (25--86)         ND                   ND      550                            94 (17)                    PET                      Prospective
  Chang           2004                  54 (35--76)         Consecutive          ND      27                             18 (67)                    PET                      ND
  Grisaru         2004                  56 (20--85)         Consecutive          Yes     12                             10 (83)                    PET/CT                   ND
  Sakurai         2006                  56 (27--80)         Consecutive          ND      54                             87%                        PET                      ND
  Amit            2006                  50 (31--71)         ND                   ND      28                             7 (25)                     PET/CT                   ND
  Sironi          2007                  28--69              Consecutive          Yes     12                             5 (42)                     PET/CT                   Retrospectively
  Chung           2007                  53 (32--77)         ND                   ND      32                             28 (88)                    PET/CT                   Retrospectively
  van der Veldt   2008                  41 (27--61)         ND                   ND      39                             25 (64)                    PET                      Retrospectively
  Kitajima        2008                  58 (37--78)         Consecutive          Yes     52                             25 (48)                    PET/CT, PET              ND
  Mittra          2009                  50 (28--87)         ND                   ND      30                             24 (80)                    PET/CT                   Retrospectively
  Pallardy        2010                  46 (35--81)         ND                   ND      40                             33 (83)                    PET/CT                   Retrospectively
  Cetrina         2011                  47                  ND                   ND      16                             12 (75)                    PET/CT                   Retrospectively
  Lee             2011                  ND                  ND                   ND      51                             37 (73)                    PET/CT                   Retrospectively

###### 

TP, FP, FN, TN and other features of PET alone

  Author          18F-FDG dose         TP   FP   FN   TN
  --------------- -------------------- ---- ---- ---- -----
  Park            2.5 MBq/kg           18   1    0    17
  Sun             ND                   16   0    2    2
  Nakamoto        370 MBq              5    6    0    9
  Belhocine       164.28--249.38 MBq   25   3    0    10
  Ryu             370--555 MBq         28   52   3    166
  Havrilesky      0.14 mCi/kg          12   2    2    13
  Lai             370 MBq              61   6    6    327
  Yen             ND                   84   8    10   448
  Chang           370 MBq              17   2    1    7
  Sakurai         200--400 MBq         43   3    4    4
  Kitajima        4.0 MBq/kg           20   6    5    21
  van der Veldt   370 MBq              23   1    2    13

###### 

TP, FP, FN, TN and other features of PET-CT

  Author     18F-FDG dose   TP   FP   FN   TN
  ---------- -------------- ---- ---- ---- ----
  Grisaru    370--666 MBq   10   0    0    2
  Chung      555--740 MBq   28   4    3    17
  Amit       370--555 MBq   6    0    1    4
  Sironi     370 MBq        5    0    1    6
  Kitajima   4.0 MBq/kg     23   2    2    25
  Mittra     400--555       22   2    1    5
  Pallardy   6 MBq/kg       31   1    2    6
  Cetina     ND             12   2    0    2
  Lee        370--555 MBq   36   4    1    10

###### 

TP, FP, FN, TN and other features of CT

  Author    Method         Section \[mm\]   TP   FP   FN   TN
  --------- -------------- ---------------- ---- ---- ---- ----
  Wlash     Not enhanced   ND               27   2    2    0
  Heron     Not enhanced   8                24   2    2    36
  William   Not enhanced   ND               10   2    1    7
  Park      Not enhanced   10               14   3    4    15

Summary estimates of the sensitivity, specificity, and diagnostic odds ratio {#S20010}
----------------------------------------------------------------------------

The pooled sensitivities for 18F-FDG PET, FDG-PET/CT, and CT were 91% (95% CI: 88--94), 94% (95% CI: 90--97), and 89% (95% CI: 81--95), respectively. No statistically significant difference was found among the three noninvasive modalities (*p* \> 0.05). In addition, the pooled specificities for the three modalities were 92% (95% CI: 90--94), 84% (95% CI: 75--91), and 87% (95% CI: 76--94), respectively. Therefore, for the specificity estimates, PET had a higher pooled sensitivity (*p* \< 0.05) compared with PET/CT. No statistical difference was found between PET/CT and CT in terms of their pooled specificities (*p* \> 0.05). The forest plots for the sensitivities and specificities of 18F-FDG PET, FDG-PET/CT, and CT are shown in [Figures 1](#F0001){ref-type="fig"}--[3](#F0003){ref-type="fig"}.

![Sensitivity **(A)** and specificity **(B)** of PET alone](AMS-10-22703-g001){#F0001}

![Sensitivity **(A)** and specificity **(B)** of PET/CT](AMS-10-22703-g002){#F0002}

![Sensitivity **(A)** and specificity **(B)** of CT](AMS-10-22703-g003){#F0003}

Diagnostic odds ratio expresses the odds of having the disease for people with a positive test result compared with those with a negative test result. The pooled DOR for PET alone was 74.15 (95% CI: 27.04--203.32), with the heterogeneity χ^2^ at 71.08 (*p* = 0.0001). The pooled DOR for PET/CT was 62.74 (95% CI: 27.82--141.47), with the heterogeneity χ^2^ at 0.00 (*p* = 0.9911). Meanwhile, the DOR for CT was 29.31 (95% CI: 5.46--157.31), with the heterogeneity χ^2^ at 53.5 (*p* = 0.0916). The results are also shown in [Figure 4](#F0004){ref-type="fig"} ([Table V](#T0005){ref-type="table"}).

![DOR of PET **(A)** alone, PET/CT **(B)**, and CT **(C)**](AMS-10-22703-g004){#F0004}

###### 

Summary estimates of sensitivity, specificity, DOR, \*Q index and AUC for PET, PE/CT and CT

  Modality   Pooled sensitivity (95% CI)   Pooled specificity (95%CI)   DOR                     \*Q      AUC
  ---------- ----------------------------- ---------------------------- ----------------------- -------- --------
  PET        91% (88--94%)                 92% (90--94%)                74.15 (27.04--203.32)   0.9037   0.9594
  PET/CT     94% (90--97%)                 84% (75--91%)                62.74 (27.82--141.47)   0.8915   0.9508
  CT         89% (81--95%)                 87% (76--94%)                29.31 (5.46--157.31)    0.8728   0.9363

Publication bias and heterogeneity {#S20011}
----------------------------------

Begg\'s funnel plot and Egger\'s test were performed to determine the publication bias of the literature. The shapes of the funnel plots do not reveal any evidence of obvious asymmetry ([Figure 5](#F0005){ref-type="fig"}). Accordingly, Egger\'s test was used to provide statistical evidence of the observed funnel plot symmetry. The results still do not suggest any evidence of a publication bias (*p*, PET = 0.681; *p*, PET/CT = 0.677 and *p*, CT = 0.497). Regarding the limited number of data points for CT imaging, current results do not show evidence of any publication bias.

![Begg\'s funnel plots for assessing the publication bias risk of PET **(A)**, PET/CT **(B)** and CT **(C)**](AMS-10-22703-g005){#F0005}

For the PET and CT studies, the specificity (heterogeneity χ^2^: 138.75 and 11.44; *p \<* 0.001 and 0.0096, respectively) was highly heterogeneous and affected the diagnostic value of PET and CT in diagnosing patients with current cervical cancer. Thus, the REMs were selected. No significant heterogeneity was found among the PET/CT studies.

Summary of the receiver operating characteristic curves and area under the curve {#S20012}
--------------------------------------------------------------------------------

We used SROC analysis to compare the noninvasive modalities. The SROC curves for 18F-FDG PET, PET/CT, and CT are shown in [Figure 6](#F0006){ref-type="fig"}. Given the heterogeneity, we chose REM to synthesize the ROC curves for 18F-FDG PET and CT, whereas FEM was used for PET/CT. The AUC values of 18F-FDG PET, PET/CT, and CT were 0.9594, 0.9508, and 0.9363, respectively ([Figure 6](#F0006){ref-type="fig"}). However, no significant difference was found among the three imaging modalities (*p* \> 0.05).

![SROC curves of PET **(A)**, PET/CT **(B)** and CT **(C)** for detecting recurrent cervical cancer](AMS-10-22703-g006){#F0006}

Discussion {#S0013}
==========

Cancer of the uterine cervix (cervical cancer) is among the top three leading diagnoses among gynecological malignancies worldwide. This disease has a relatively high 5-year mortality and recurrence rate (28%). Hence, enhanced staging, therapy, and evaluation of recurrence are essential to improve the prognosis for cervical cancer patients \[[@CIT0032]\]. The current meta-analysis focused on evaluating the diagnostic efficiency of PET, PET/CT, and PET in the diagnosis of recurrent cervical cancer.

Positron emission tomography and positron emission tomography/computed tomography {#S20014}
---------------------------------------------------------------------------------

Positron emission tomography using FDG has been successfully used to diagnose cancer recurrence and distant metastasis in the preclinical stage before the disease becomes evident by conventional imaging modalities. Positron emission tomography provides anatomical image resolutions from 4 mm to 6 mm, which are significantly better than those of conventional gamma cameras but inferior to the 1 mm to 2 mm resolution of CT or MRI. Our results confirm that FDG-PET may be a useful modality in detecting the recurrence of cervical cancer, exhibiting high sensitivity at 91% and high specificity at 92%. Ryu *et al*. \[[@CIT0016]\] reported that the sensitivity and specificity of 18F-FDG PET were 90.3% and 76.1%, respectively, for the detection of early recurrence in 249 patients with no evidence of the disease on physical examination and had negative tumor markers, chest radiography, and annual pelvic CT or MRI. Sugawara *et al*. \[[@CIT0033]\] reported that 18F-FDG PET can detect lymph node metastasis more accurately than CT or MRI in patients with cervical cancer. 18F-FDG PET can detect recurrences in small lesions (\< 1 cm) and in the retrovesical area, which are frequently obscured by postradiation fibrosis. Chung *et al*. \[[@CIT0025]\] found that the sensitivity and specificity of FDG-PET for detecting recurrence in patients who had elevated serum SCC-Ag levels and negative conventional imaging findings were 94% and 78%, respectively. Therefore, PET alone may be useful in the early diagnosis of recurrence, particularly when SCC levels are increasing and conventional imaging (e.g., CT or MR imaging) is inconclusive or negative. However, PET does not provide sufficient structural information for direct topographical evaluation. Thus, image analysis has to be based on additional anatomical information \[[@CIT0034]\]. An integrated PET/CT system, in which a dedicated PET ring and a multidetector helical CT are combined, has recently facilitated the acquisition of both metabolic and anatomical imaging data using a single device in a single diagnostic session. This integrated system provides precise anatomical localization of suspicious areas with increased FDG uptake and rules out false-positive PET findings \[[@CIT0035]\]. The use of combined PET/CT in detecting re-current cervical cancer was first described by Grisaru *et al*. in 2004. They reported that the sensitivity and specificity of PET/CT for detecting recurrent cervical cancer were both 100%. A limitation of this pilot study is that the number of enrolled suspected recurrent cervical cancer patients was not sufficient for a powerful statistical analysis. In our meta-analysis, we found no significant difference between PET alone and PET/CT (*p* \> 0.05). A possible explanation for this discrepancy is that the accuracy of PET/CT may have been compromised by inflammatory lesions induced by recent surgery or radiotherapy. However, the use of PET/CT can help identify biopsy sites, avoiding the interpretation problems resulting from poor anatomic localization of PET alone. A further CT scan may be based on a positive FDG PET scan.

Computed tomography {#S20015}
-------------------

Computed tomography is often used in postoperative, follow-up examinations of patients after cervical cancer surgery. Choi *et al*. \[[@CIT0036]\] performed a meta-analysis to assess the diagnostic performances of CT and PET or PET/CT for the detection of metastatic lymph nodes in patients with cervical cancer. Computed tomography was reported to show pooled sensitivity and specificity of 50% and 92%, respectively, whereas PET or PET/CT showed 82% and 95%, respectively. Park *et al*. \[[@CIT0012]\] also reported that PET is superior to CT in terms of sensitivity and specificity. Walsh *et al*. \[[@CIT0003]\] found that CT has difficulty in differentiating recurrence from postoperative and postradiation fibrosis and in detecting normal-sized metastatic lymph nodes. These findings suggest that PET may be crucial in detecting recurrent cervical cancer when CT results are negative.
